Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study to Evaluate IMM27M Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity in Patients With Advanced, Metastatic Solid Tumor

Next Previous
Trial Profile

A Phase 1 Study to Evaluate IMM27M Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity in Patients With Advanced, Metastatic Solid Tumor

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Jan 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tazlestobart (Primary)
  • Indications Advanced breast cancer; Carcinoma; Colorectal cancer; Endometrial cancer; Head and neck cancer; Liver cancer; Male breast cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Renal cell carcinoma; Small cell lung cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer
  • Focus Adverse reactions; First in man
  • Sponsors ImmuneOnco Biopharma

Most Recent Events

  • 06 Jan 2026 According to an Instil Bio media release, Axion and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. have entered into an agreement to terminate their license and collaboration agreement for AXN-27M.
  • 13 Aug 2024 According to an Instil Bio media release, the phase Ia dose escalation study has been completed, the study continue enrolling in dose optimization and dose expansion part
  • 10 Apr 2024 Results ( As of 3 Nov 2023, n=25) presented at the 115th Annual Meeting of the American Association for Cancer Research

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top